ZIF-8 Nanocarrier-Based Co-Delivery of Curcumin and 5-Fluorouracil for Synergistic Antitumor Activity in Hepatocellular Carcinoma Authors: Long Zhang, Weijie Zhu, Lei He, Yuehan Zhang, Haibo Yang, Jinbao Xiao, Jiayi Zhao, Yunfei Huang, Jiannan Li Published: 2026 ABSTRACT BackgroundHepatocellular carcinoma (HCC) is a highly prevalent malignancy worldwide, posing a severe threat to human health. Although conventional chemotherapy remains a primary treatment modality, its clinical efficacy is limited by poor targeting, drug resistance, and systemic toxicity. To address these challenges, this study developed a zeolitic imidazolate framework-8 (ZIF-8)-based nanoplatform with pH-responsive behavior for dual-loading of 5-fluorouracil (5-FU) and curcumin (CUR).MethodsIn this study, a ZIF-8-based nanoplatform with pH-responsive behavior was developed for the co-delivery of 5-FU and CUR. The ZIF-8@5-FU/CUR nanocomposite was comprehensively characterized to evaluate its structural stability, drug-loading capacity, and drug-delivery efficiency. Its antitumor activity was subsequently evaluated using in vitro and in vivo experimental models.ResultsThe ZIF-8@5-FU/CUR nanocomposite exhibited stable drug-loading properties and efficient co-delivery of 5-FU and CUR. In vitro experiments demonstrated significant cytotoxicity of the co-delivery system against HepG2 cells, resulting in extensive tumor cell death and superior antitumor activity compared with single-drug formulations. In vivo studies further showed that ZIF-8@5-FU/CUR effectively inhibited tumor growth by suppressing tumor cell proliferation, promoting apoptosis, and alleviating inflammation and oxidative stress. Moreover, the nanocomposite exhibited favorable biocompatibility.ConclusionThe ZIF-8@5-FU/CUR nanocomposite demonstrates potential as a safe and effective co-delivery system for HCC therapy. Its pH-responsive drug delivery and combined antitumor effects suggest that ZIF-8-based nanocarriers may provide a promising strategy for precision cancer therapy. Introduction Liver cancer ranks among the most common malignancies worldwide and occupies a dominant position in cancer-related mortality.1 Its incidence rate has shown a steady increase across numerous countries over recent decades,2 accounting for nearly 1 million new cases annually.3 Recent molecular and multi-omic studies have highlighted the biological heterogeneity of HCC, identifying alterations in the tumor microenvironment, prognostic proteins, and LncRNAs that may contribute to disease progression and therapeutic response.4–6 Systemic therapy remains an important treatment modality for patients with advanced hepatocellular carcinoma (HCC).7 However, conventional chemotherapy is constrained by factors such as low precision in drug delivery, rapid in vivo degradation, suboptimal therapeutic efficacy, and minimal extension of patient survival time.8 In contrast, targeted chemotherapy has emerged as a promising approach, enabling selective drug delivery to cancer cells and minimizing adverse effects while enhancing treatment outcomes.9 Targeted HCC therapy primarily involves two components: chemotherapeutic agents and targeted drug delivery systems. Regarding chemotherapeutic agents, the limitations of monotherapy—such as inadequate efficacy and drug resistance—have underscored the growing importance of combination therapy as an effective anticancer strategy.10 In particular, traditional chemotherapeutics combined with natural plant-derived drugs have gained significant attention.11 Natural plant-derived compounds have shown considerable potential in HCC treatment through regulation of specific molecular targets. For example, a recent study demonstrated that matrine targeted Annexin A2 and restored tumor-associated antigen presentation, thereby enhancing antitumor immune responses in liver cancer.12 Other studies have further explored the therapeutic potential and molecular basis of bioactive compounds derived from medicinal plants, such as Salvia miltiorrhiza, in HCC.13 These findings further highlight the potential of natural compounds as complementary agents for HCC treatment. For targeted drug delivery systems, conventional carriers often feature low drug-loading capacity and poor stability. Recent advances in nanocarrier design have focused on improving tumor targeting, biological barrier penetration, and controlled drug delivery.14,15 Importantly, a recent analysis of multi-drug cancer nanomedicine showed that co-delivery of multiple agents within the same nanocarrier can provide greater antitumor efficacy than free-drug combinations or separate nanomedicine delivery.16 Among various nanocarrier platforms, metal-organic frameworks (MOFs) ingeniously integrate the advantages of inorganic and organic (highly biocompatible) nanocarriers, thereby offering a balanced and efficient drug delivery platform.17,18 Recent studies have demonstrated that the biodegradation behavior of MOFs can be regulated to achieve tumor-specific drug release and improve therapeutic efficacy.19 Among MOFs, zeolitic imidazolate framework-8 (ZIF-8) is constructed through coordination between zinc ions (Zn2+) and 2-methylimidazole (2-Mim) ligands. ZIF-8 exhibits high stability under physiological conditions, which may help reduce premature drug leakage. However, the Zn-N coordination bonds in typical ZIF-8 undergo protonation and cleavage triggered by the weakly acidic tumor microenvironment (TME); subsequent structural disintegration facilitates controlled and precise drug release. This pH-responsive behavior aligns well with the requirements of tumor-targeted drug delivery. In this study, we combined the chemotherapeutic agent 5-fluorouracil (5-FU) with the natural plant-derived compound curcumin (CUR) for HCC treatment. 5-FU is an antimetabolite widely used in liver cancer therapy that inhibits DNA synthesis by targeting thymidylate synthase (TS). However, its clinical application is restricted by side effects such as toxicity to normal cells, which compromise therapeutic efficacy.20 To address these limitations, 5-FU has been integrated with other anticancer drugs, including cisplatin,21 paclitaxel,22 and CUR.23 CUR, a lipophilic polyphenol derived from Curcuma longa rhizomes, has been used in traditional medicine for several decades. Accumulating evidence has demonstrated its anti-inflammatory,24 antioxidant,25 and anticancer activities,26 establishing it as a key focus in pharmacological research. Mechanistically, CUR exerts inhibitory effects on cell proliferation-related proteins, downregulates growth factor receptors, and suppresses both anti-apoptosis and angiogenesis-promoting proteins.27 Notably, CUR induces less cytotoxicity toward normal somatic cells relative to conventional chemotherapeutic agents. Furthermore, 5-FU and CUR impose antitumor effects through distinct mechanisms, supporting their combined applicability in cancer chemotherapy.20,28 Although the co-delivery of 5-FU and CUR has been reported using other nanocarriers,23 their co-delivery using a ZIF-8-based platform for HCC treatment remains insufficiently explored. Therefore, we constructed a ZIF-8-based nanoscale co-delivery system for hydrophilic 5-FU and hydrophobic CUR and evaluated its antitumor performance in HCC. In light of these findings, the present study aimed to design and construct a ZIF-8-based nanoscale co-delivery system capable of simultaneously loading hydrophilic 5-FU and hydrophobic CUR. The construction methods and potential biological basis are illustrated in Graphical Abstract. The system incorporates three main features. First, the high porosity of ZIF-8 enables the co-loading of 5-FU and CUR despite their distinct physicochemical properties, while its pH-responsive behavior facilitates drug release in the weakly acidic TME. Second, the nanocarrier may improve drug performance by facilitating the delivery of hydrophobic CUR and protecting 5-FU from premature degradation. Third, the combined delivery of 5-FU and CUR is expected to enhance antitumor activity through complementary effects on tumor cells. Through passive tumor targeting and triggered drug release, this system is expected to improve tumor-cell killing while reducing systemic toxicity. Overall, this study not only presents a novel strategy for improving combination chemotherapy but also demonstrates the potential of multifunctional MOF-based nanoplatforms in precision cancer therapy. Materials and Methods Details of materials, instruments, cell lines used and the legends information are provided in the Supporting Information. Preparation of ZIF-8@Drug Four types of nanoparticles (NPs) were synthesized at room temperature using a one-pot direct encapsulation strategy.29 All formulations maintained a constant Zn2+:2-Mim molar ratio of 1:8. Briefly, the specific drug to be loaded (5-FU, CUR, or their combination mixed at feeding ratios of 1:1, 1:2, and 2:1) was co-dissolved with zinc acetate in neat methanol and stirred at 800 rpm for 5 min. Subsequently, a methanolic solution of 2-Mim was added dropwise, and the mixture was continuously stirred at 800 rpm for another 60 min. The resulting precipitate was collected by centrifugation (10,000 rpm, 10 min), washed repeatedly with ethanol and distilled water, and lastly vacuum-dried at 20–25 °C for 12 h. Characterization of ZIF-8@Drug Physicochemical Characterization We systematically characterized the morphology, crystalline phase, chemical structure, and functional groups of the NPs before and after drug loading, and determined the drug loading content (DLC). In vitro Drug Release In vitro release of 5-FU and CUR from ZIF-8@5-FU/CUR was assessed at 37 °C in buffer solutions at pH 5.5 and pH 7.4, representing an acidic tumor-microenvironment condition and a physiological pH condition, respectively. Experiments were performed in triplicate. The nanoformulation was immersed in 2 mL of buffer solution and incubated under continuous shaking at 60 rpm at 37 °C. Aliquots of the suspension were withdrawn at predefined time points, followed by centrifugation at 10,000 rpm for 2 min, and sequential filtration. The concentrations of released 5-FU and CUR were quantified at 265 nm and 450 nm, respectively, using ultraviolet-visible (UV-vis) spectrophotometry. In vitro Studies Unless otherwise specified, the in vitro experiments were divided into the following four groups: ZIF-8, ZIF-8@5-FU, ZIF-8@CUR, and ZIF-8@5-FU/CUR. Cell Cytotoxicity Assay (CCK-8) HepG2 cells were trypsinized, resuspended, and seeded into 96-well plates (The cells were cultured routinely in an incubator at 37 °C with 5% CO2 and saturated humidity, and the medium was changed every 2–3 days). The next day, the medium was switched to serum-free DMEM comprising varying concentrations (0, 15, 31, 62.5, 125, 250, 500, 1000, 2000 μg/mL). Post 48 h of incubation, cells were gently rinsed twice with PBS, and 100 μL of fresh complete medium containing 10 μL CCK-8 solution was added to each well. Following an additional 2 h incubation, absorbance was recorded at 450 nm. Hemolysis Assay Mouse whole blood (1 mL) was centrifuged at 1,000 × g for 10 min. Red blood cells (RBCs) were washed three times with precooled PBS and diluted to 4%. ZIF-8, ZIF-8@5-FU, ZIF-8@CUR, and ZIF-8@5-FU/CUR suspensions (0–500 μg/mL, 50 μL) were mixed with 50 μL of RBC suspension in 96-well plates. Deionized water and PBS were used as positive and negative controls, respectively. After incubation at 37 °C for 3 h, samples were centrifuged at 1,000 × g for 15 min, and the absorbance of the supernatant was measured at 570 nm. Each condition was performed in triplicate. Hemolysis was calculated as: \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$$\mathrm{Hemolysis\,{\mathrm{ }}\left( \% \right){\mathrm{ }} = {\mathrm{ }}\left( {O{D_{sample}} - {\mathrm{ }}O{D_{negative}}} \right){\mathrm{ }}/{\mathrm{ }}\left( {O{D_{positive}} - {\mathrm{ }}O{D_{negative}}} \right){\mathrm{ }} \times {\mathrm{ }}100\%}$$\end{document} Live/Dead Cell Staining Assay HepG2 cells were initially cultured in 12-well plates overnight and then treated with serum-free DMEM containing 125 μg/mL of the four NPs for 48 h. Next, cells were gently washed twice and stained with 1 mL Calcein-AM/PI working solution for 30 min at 37 °C in the dark. After a final PBS wash, fluorescence images were immediately captured (live cells: Calcein-AM, Ex/Em=494/517 nm, green; dead cells: PI, Ex/Em=535/617 nm, red). Live cell counts and viability rates were calculated using ImageJ software. Cell Apoptosis Assay HepG2 cells were cultured in 12-well plates for 24 h to allow adherence. Subsequently, cells were exposed to 125 μg/mL of the four NPs for 48 h, with an additional PBS group included as the untreated control. Afterwards, all cells were collected by treating with EDTA-free trypsin (37 °C, 5 min) and centrifuged at 700 × g for 5 min. Cell pellets were washed twice with PBS and then stained with 0.5 μL Annexin V-FITC (10 min, room temperature, dark) and 1 μL 7-AAD (5 min, room temperature, dark). Finally, samples were filtered through a 200-mesh sieve and immediately analyzed by flow cytometry to quantify apoptotic cell populations. In vivo Studies Antitumor Efficacy The efficacy was evaluated in male Balb/c mice inoculated with H22 cells. The male Balb/c mice were purchased from Animal Experimental Center of Jilin University (Approved No.: KT202408007; Animal License No.: SYXK(JI)2026–0014). The in vivo animal assays were implemented in accordance with protocols reviewed and authorized by the Institutional Animal Care and Use Committee. Upon reaching ~100 mm3 volume, mice were randomly divided into four groups (n = 6): (I) ZIF-8, (II) ZIF-8@5-FU, (III) ZIF-8@CUR, and (IV) ZIF-8@5-FU/CUR. NP formulations were administered via tail vein injection at 20 mg/kg (based on total nanoparticle mass) every 2 d over 12 d. Tumor volumes were monitored at 2-day intervals and calculated as V = L × W2/2 (L and W represent the longest and shortest diameters, respectively). Tumor growth was expressed as V/V0, with V0 denoting the initial tumor volume at the start of treatment. Body weight was recorded regularly during the treatment period. Upon completion of the study at the fourteenth day, mice were euthanized by cervical dislocation; tumors were excised, weighed, and used to determine the tumor inhibition rate per group as: (Wt and Wc represent the tumor weight of treatment and control group). \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$$\mathrm{Tumor\,{\mathrm{ }}inhibition\,{\mathrm{ }}ratio\,{\mathrm{ }}\left( \% \right){\mathrm{ }} = {\mathrm{ }}\left( {1{\mathrm{ }} - {\mathrm{ }}Wt/Wc} \right){\mathrm{ }} \times {\mathrm{ }}100\%}$$\end{document} Major organs (heart, liver, spleen, lungs, and kidneys) and tumor tissues were subjected to hematoxylin and eosin (H&E) staining to determine antitumor efficacy and safety of the ZIF-8-based drug-loaded NPs in vivo. Immunohistochemical (IHC) Analysis Expression levels of Ki67, BAX, COX2, and NOX2 in tumor tissues were determined by IHC staining to further explore the potential biological basis. For quantitative IHC analysis, three non-overlapping fields were randomly selected from viable tumor regions of each section and examined at ×200 magnification.30 Necrotic, hemorrhagic, folded areas were excluded, and cells showing clear brown DAB staining above background were considered positive. The same criteria were applied consistently across all groups for each marker. Data Statistics Data are presented as mean ± standard deviation (SD). Statistical analysis involved Student’s t-test for two-group comparisons and one-way analysis of variance (ANOVA) for multiple group comparisons. Significance levels were defined as follows: ns (not significant), *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Results Characterization of ZIF-8@Drug Morphology, Size, and Structural Characterization As illustrated in Figure 1A–E, the four NP formulations presented a uniform rhombic dodecahedral morphology, highlighting the peculiar crystalline structure of ZIF-8. These features indicate that drug incorporation did not significantly alter the intrinsic crystal habit of ZIF-8. The particle size fell within the optimal range for passive tumor targeting. Energy Dispersive X-Ray Spectroscopy (EDS) (Figure 1F) detected the homogeneous distribution of elemental components (C, N, Zn) within ZIF-8.Figure 1Characterization of ZIF-8@Drug (A–D) Transmission electron microscopy (TEM) images of (A) ZIF-8, (B) ZIF-8@5-FU, (C) ZIF-8@CUR, and (D) ZIF-8@5-FU/CUR. (E) Scanning electron microscopy (SEM) image of the ZIF-8@5-FU/CUR composite. (F) Energy-dispersive X-ray spectroscopy (EDS) elemental mapping of C, N, and Zn in pristine ZIF-8. (G) Hydrodynamic size distribution determined by dynamic light scattering (DLS). (H) Zeta potential of nanoparticles (NPs). (I) X-ray diffraction (XRD) patterns of ZIF-8 and ZIF-8@5-FU/CUR composite. (J) Fourier transform infrared (FTIR) spectra of all four NP formulations. (K) UV-Vis absorption spectra of ZIF-8, 5-FU, CUR, ZIF-8@5-FU, ZIF-8@CUR, and ZIF-8@5-FU/CUR composite. (L and M) Standard calibration curves for 5-FU (L) and CUR (M) quantification. (N and O) In vitro cumulative release profiles of 5-FU and CUR from ZIF-8@5-FU/CUR in PBS at pH 5.5 (N) and pH 7.4 (O) at 37 °C.Infographic on ZIF-8 drug-loaded nanoparticles, showing characterization and release profiles.The infographic illustrates the characterization and release profiles of ZIF-8 drug-loaded nanoparticles. Panels A to F show microscopy images: TEM images of ZIF-8, ZIF-8@5-FU, ZIF-8@CUR and ZIF-8@5-FU/CUR, highlighting consistent polyhedral shapes. SEM and EDS maps reveal particle clustering and elemental distribution of C, N, Zn. Panels G to H present bar charts of DLS sizes and Zeta potentials, indicating size differences and negative potentials. Panels I to K display XRD, FTIR and UV-Vis spectra, showing structural consistency and absorption features. Panels L to M provide calibration curves for 5-FU and CUR, with equations and R values. Panels N to O depict cumulative release profiles, showing sustained release over time with approximate final percentages. The infographic demonstrates successful drug loading and sustained release behavior. Characterization of ZIF-8@Drug (A–D) Transmission electron microscopy (TEM) images of (A) ZIF-8, (B) ZIF-8@5-FU, (C) ZIF-8@CUR, and (D) ZIF-8@5-FU/CUR. (E) Scanning electron microscopy (SEM) image of the ZIF-8@5-FU/CUR composite. (F) Energy-dispersive X-ray spectroscopy (EDS) elemental mapping of C, N, and Zn in pristine ZIF-8. (G) Hydrodynamic size distribution determined by dynamic light scattering (DLS). (H) Zeta potential of nanoparticles (NPs). (I) X-ray diffraction (XRD) patterns of ZIF-8 and ZIF-8@5-FU/CUR composite. (J) Fourier transform infrared (FTIR) spectra of all four NP formulations. (K) UV-Vis absorption spectra of ZIF-8, 5-FU, CUR, ZIF-8@5-FU, ZIF-8@CUR, and ZIF-8@5-FU/CUR composite. (L and M) Standard calibration curves for 5-FU (L) and CUR (M) quantification. (N and O) In vitro cumulative release profiles of 5-FU and CUR from ZIF-8@5-FU/CUR in PBS at pH 5.5 (N) and pH 7.4 (O) at 37 °C. Dynamic light scattering (DLS) results (Figure 1G) revealed an average hydrodynamic diameter of approximately 150 nm and no marked difference in size after drug loading, indicative of good NP dispersity and stability in PBS. Zeta potential measurements (Figure 1H) reflected a surface potential of +8.0 mV for pristine ZIF-8, originating from the coordinatively unsaturated Zn2+ sites. Following drug loading, the Zeta potential of ZIF-8@5-FU/CUR decreased to −4.5 mV, likely due to the neutral 5-FU and hydrophobic CUR molecules occupying partial surface sites and moderately shielding the positive charge. This shift further corroborates the successful drug encapsulation. X-ray diffraction (XRD) pattern of ZIF-8@5-FU/CUR displayed sharp peaks located at 2θ = 7.2°, 10.4°, 12.6°, 17.9°, and 26.7°, corresponding to the (011), (002), (112), (222), and (134) planes, respectively. These peaks are consistent with those of pristine ZIF-8, indicating preserved crystallinity of samples (Figure 1I). Notably, no characteristic crystalline peaks of either 5-FU or CUR were observed after drug loading, suggesting that both drugs were dispersed in an amorphous state within the pores or cavities of ZIF-8. Chemical Composition and Loading Confirmation Fourier transform infrared (FTIR) spectroscopy further confirmed the successful drug loading. The spectrum of ZIF-8@5-FU/CUR exhibited distinctive peaks of the ZIF-8 framework at 420 cm−1 and 1588 cm−1 (Figure 1J), attributed to Zn-N stretching vibrations and N–O asymmetric stretching, respectively. Meanwhile, additional absorption peaks were observed, featuring an O–H stretching band at 3507 cm−1 and a C–F stretching vibration at 1145 cm−1. The appearance of these characteristic peaks directly demonstrates the satisfactory loading of both 5-FU and CUR into the ZIF-8 nanocarrier. Furthermore, UV-Vis spectrophotometric analysis revealed a distinct peak at 450 nm (Figure 1K), verifying the effective encapsulation of CUR within the NPs. DLC and Encapsulation Efficiency (EE) DLC and EE of ZIF-8@5-FU/CUR were estimated by quantifying the residual drug concentration in the supernatant after synthesis and centrifugation. Specifically, the absorbance of the supernatant (obtained after centrifuging the synthesized NPs) was precisely measured at the maximum absorption wavelengths of 5-FU (265 nm) and CUR (450 nm). The concentration of unencapsulated drug was calculated using pre-established standard calibration curves (Figure 1L and M), allowing the determination of DLC within the NPs. The results indicated significant differences in EE and DLC among different drug feeding ratios, as listed in Table 1. The 1:1 feed ratio, owing to its relatively high DLC and EE, was selected for the dual-drug system. For this formulation (1:1 feed ratio), the DLC and EE values were: 5-FU: 4.5% and 74.0%; CUR: 5.3% and 72.9%. Comparatively, single-drug systems exhibited a DLC of 7.7% with an EE of 83.7% for 5-FU and 13.2% DLC with an EE of 76.2% for CUR.Table 1Encapsulation Efficiency and Drug Loading Content of ZIF-8@Drug Formulations5-FU:CUR5-FUCUREncapsulation EfficiencyDrug LoadingEncapsulation EfficiencyDrug Loading1:0174.00%4.50%72.90%5.30%1:0272.50%3.50%70.20%5.60%2:0173.60%4.60%57.80%4.50% Table 1Encapsulation Efficiency and Drug Loading Content of ZIF-8@Drug Formulations5-FU:CUR5-FUCUREncapsulation EfficiencyDrug LoadingEncapsulation EfficiencyDrug Loading1:0174.00%4.50%72.90%5.30%1:0272.50%3.50%70.20%5.60%2:0173.60%4.60%57.80%4.50% Encapsulation Efficiency and Drug Loading Content of ZIF-8@Drug Formulations In Vitro Drug Release In vitro drug release from ZIF-8@5-FU/CUR was estimated using UV-Vis spectrophotometry. As shown in Figure 1N and O, drug release from ZIF-8@5-FU/CUR was markedly dependent on pH. At pH 5.5, the cumulative release over 72 h reached 82.2% for CUR and 72.5% for 5-FU (Figure 1N). In contrast, at pH 7.4, the cumulative release at 72 h was only 23.3% for CUR and 19.7% for 5-FU (Figure 1O). Cell Cytotoxicity Assay All NP formulation groups exhibited a concentration-dependent suppression in HepG2 cell proliferation (P < 0.05, Figure 2A). At 0 μg/mL, cell viability in all groups remained close to 100%. Upon reaching the highest concentration of 2000 μg/mL, cell viability decreased to 6.6%, 7.0%, 12.3%, and 8.4% in the ZIF-8, ZIF-8@5-FU, ZIF-8@CUR, and ZIF-8@5-FU/CUR groups, respectively. At 250 μg/mL, the ZIF-8@5-FU/CUR group demonstrated significantly greater cytotoxicity than the other three groups, with an IC50 value of 178.7 μg/mL. These findings imply that the combined application of 5-FU and CUR produces a synergistic cytotoxic effect against HepG2 cells.Figure 2In vitro cytotoxicity and hemocompatibility of the four nanoparticle formulations in HepG2 cells. (A) Concentration-dependent cell viability assessed by cytotoxicity assay (CCK-8); (B) Hemolysis rate of each formulation at varying concentrations; (C–F) Hemolysis profiles of (C) ZIF-8, (D) ZIF-8@5-FU, (E) ZIF-8@CUR, and (F) ZIF-8@5-FU/CUR. Data are presented as mean ± SD (n = 3).Graphs and images show cell viability and hemolysis rates of ZIF-8 formulations at various concentrations.A line graph showing cell viability against concentration for ZIF-8, ZIF-8@CUR, ZIF-8@5-FU and ZIF-8@5-FU/CUR. Concentrations range from 15.625 to 2000 microg/mL. A second graph shows hemolysis percentage for the same formulations, with concentrations from 15.625 to 500 microg/mL. Images C, D, E and F display test tubes with varying concentrations of ZIF-8, ZIF-8@5-FU, ZIF-8@CUR and ZIF-8@5-FU/CUR, respectively, alongside graphs of hemolysis rates. Concentrations are labeled from 0 to 500 microg/mL, with water as a reference. Hemolysis rates are shown for each formulation, indicating minimal hemolysis at lower concentrations and increased hemolysis at higher concentrations, particularly with water. In vitro cytotoxicity and hemocompatibility of the four nanoparticle formulations in HepG2 cells. (A) Concentration-dependent cell viability assessed by cytotoxicity assay (CCK-8); (B) Hemolysis rate of each formulation at varying concentrations; (C–F) Hemolysis profiles of (C) ZIF-8, (D) ZIF-8@5-FU, (E) ZIF-8@CUR, and (F) ZIF-8@5-FU/CUR. Data are presented as mean ± SD (n = 3). Hemolysis Assay The hemolysis assay indicated that all NP formulations maintained favorable hemocompatibility within the tested concentration range (0–500 μg/mL) (Figure 2B–F). At 250 μg/mL, the respective hemolysis rates for ZIF-8, ZIF-8@5-FU, ZIF-8@CUR, and ZIF-8@5-FU/CUR NPs were 1.47%, 2.26%, 1.83%, and 3%. According to the ASTM F756-based classification commonly used for hemocompatibility assessment, hemolysis values >5% are considered hemolytic.31 Accordingly, all values observed in the present study were below this cutoff. Live/Dead Cell Staining Assay The staining results revealed that the ZIF-8 group primarily exhibited green fluorescence (~95% live cells), confirming the low cytotoxicity of the blank carrier (Figure 3A). The ZIF-8@CUR group displayed a slight decrease in green fluorescence with sparse red fluorescence (~90% live cells), indicating mild cytotoxicity of CUR monotherapy. Inversely, the ZIF-8@5-FU group demonstrated a marked reduction in green fluorescence accompanied by an increase in red fluorescence (~50% live cells), highlighting the effective induction of HepG2 cell death by 5-FU. Notably, the ZIF-8@5-FU/CUR group presented with the highest proportion of red fluorescence (~10% live cells) than that observed in other groups (P < 0.01). These findings verify the synergistic antitumor effects of ZIF-8 encapsulated 5-FU and CUR in HepG2 cells.Figure 3In vitro live/dead staining and apoptosis analysis of ZIF-8-based drug-loaded nanoparticles in HepG2 cells. (A) Calcein-AM/PI double-staining images of HepG2 cells (×200) (i, v: ZIF-8; ii, vi: ZIF-8@CUR; iii, vii: ZIF-8@5-FU; iv, viii: ZIF-8@5-FU/CUR); (B) Annexin V-FITC/7-AAD flow cytometry dot plots of HepG2 cells (i: PBS; ii: ZIF-8; iii: ZIF-8@CUR; iv: ZIF-8@5-FU; v: ZIF-8@5-FU/CUR).A: 8 micrographs (green/red) with scale bars; B: 5 flow plots of Annexin-V vs PI with quadrant %. In vitro live/dead staining and apoptosis analysis of ZIF-8-based drug-loaded nanoparticles in HepG2 cells. (A) Calcein-AM/PI double-staining images of HepG2 cells (×200) (i, v: ZIF-8; ii, vi: ZIF-8@CUR; iii, vii: ZIF-8@5-FU; iv, viii: ZIF-8@5-FU/CUR); (B) Annexin V-FITC/7-AAD flow cytometry dot plots of HepG2 cells (i: PBS; ii: ZIF-8; iii: ZIF-8@CUR; iv: ZIF-8@5-FU; v: ZIF-8@5-FU/CUR). Apoptosis Induction Effect Flow cytometry analysis showed a low baseline level of late apoptosis in the PBS control group (1.59%) (Figure 3Bi) and the ZIF-8 group (1.06%) (Figure 3Bii). In contrast, the dual-drug delivery system effectively induced late apoptosis in HepG2 cells, with the apoptotic rate reaching 95.3% for the ZIF-8@5-FU/CUR group (Figure 3Bv). The value was considerably higher than that noted in the ZIF-8@CUR group (22.5%) (Figure 3Biii) and the ZIF-8@5-FU group (50.0%) (Figure 3Biv), highlighting a strong synergistic effect between 5-FU and CUR achieved chiefly by promoting late apoptosis in tumor cells. In vivo Antitumor Activity Evaluation Following NP administration, body weights of mice in the ZIF-8@5-FU, ZIF-8@CUR, and ZIF-8@5-FU/CUR groups increased steadily, implying good systemic tolerance and safety of the drugs. Conversely, the ZIF-8 mice group had an initial increase, followed by a gradual decline, likely attributed to progressive tumor burden (Figure 4A). Regarding tumor volume, ZIF-8@5-FU/CUR group yielded the optimal therapeutic efficacy, exceeding ZIF-8@5-FU and ZIF-8@CUR groups (Figure 4B), indicative of a synergistic antitumor action by the dual-drug-loaded system. As depicted in Figure 4C, the final tumor weights were measured, and the corresponding tumor inhibition rates were calculated accordingly (Figure 4D). The tumor inhibition rates for ZIF-8@5-FU and ZIF-8@CUR were 26.5% and 25.8%, respectively, whereas ZIF-8@5-FU/CUR achieved a significantly higher inhibition rate of 58.3%. Also, H&E staining of tumor tissues showed that ZIF-8 group had densely packed viable tumor cells with minimal necrosis, while the single-drug groups (ZIF-8@5-FU and ZIF-8@CUR) exhibited only limited local cell death, retained large areas of viable tumor tissue. In contrast, ZIF-8@5-FU/CUR group demonstrated extensive necrosis and a marked reduction in viable tumor cells (Figure 4E). Collectively, these results infer that the combined therapeutics of ZIF-8@5-FU/CUR markedly enhance the anti-hepatoma effects.Figure 4In vivo antitumor efficacy of ZIF-8-based drug-loaded nanoparticles in tumor-bearing mice. (A) Body weight changes of mice in each group during drug administration; (B) Relative tumor volume (V/V0) over time; (C) Final tumor weight at the end of the treatment; (D) Tumor inhibition rates of each group; (E) Hematoxylin and eosin (H&E) staining images of tumor tissues (i: ZIF-8; ii: ZIF-8@5-FU; iii: ZIF-8@CUR; iv: ZIF-8@5-FU/CUR). Data are presented as mean ± SD (n = 6). Statistical comparisons between two groups were performed using Student’s t-test. ****P < 0.0001.A composite figure with two line graphs, two bar charts and four tumor tissue micrographs.Image A: A line graph shows body weight (g) from 32 to 42 over 15 days. Four series are plotted: ZIF-8, ZIF-8 at CUR, ZIF-8 at 5-FU and ZIF-8 at 5-FU/CUR. One series decreases early, while others increase. Image B: A line graph displays relative tumor volume (V/V0) from 0 to 15 over 15 days. The same four series rise, with the highest near 11 and the lowest near 5 by day 15. Image C: A bar chart shows tumor weight (g) from 0 to 2.0 for ZIF-8, ZIF-8 at CUR, ZIF-8 at 5-FU and ZIF-8 at 5-FU/CUR, with heights of 1.5, 1.1, 1.1 and 0.6 grams. Brackets with asterisks indicate significance. Image D: A bar chart shows tumor inhibition ratio (%) from 0 to 80 for ZIF-8 at CUR, ZIF-8 at 5-FU and ZIF-8 at 5-FU/CUR, with heights of 26%, 26% and 58%. Image E: Four hematoxylin and eosin stained tumor tissue sections (i, ii, iii, iv) show irregular boundaries and varying staining densities, with a 200 um scale bar. In vivo antitumor efficacy of ZIF-8-based drug-loaded nanoparticles in tumor-bearing mice. (A) Body weight changes of mice in each group during drug administration; (B) Relative tumor volume (V/V0) over time; (C) Final tumor weight at the end of the treatment; (D) Tumor inhibition rates of each group; (E) Hematoxylin and eosin (H&E) staining images of tumor tissues (i: ZIF-8; ii: ZIF-8@5-FU; iii: ZIF-8@CUR; iv: ZIF-8@5-FU/CUR). Data are presented as mean ± SD (n = 6). Statistical comparisons between two groups were performed using Student’s t-test. ****P < 0.0001. IHC staining of Ki67, BAX, COX2, and NOX2 further explored the potential synergistic antitumor basis of ZIF-8@5-FU/CUR NP composite (Figure 5). For Ki67, a large number of cells stained positive in the ZIF-8 group (Figure 5A), while a moderate reduction was observed in the ZIF-8@CUR and ZIF-8@5-FU groups. Contrastingly, Ki67-positive cells in the ZIF-8@5-FU/CUR group were minimal, with a significantly lower positive rate than the ZIF-8 group (P < 0.0001) (Figure 5B). These findings indicate that the combination treatment strongly suppresses tumor cell proliferation. An analogous staining pattern was noted for COX2 expression. The positive rate difference between ZIF-8 and ZIF-8@CUR groups was statistically insignificant (Figure 5C). The COX2-positive rate was slightly reduced in the ZIF-8@5-FU group, whereas the ZIF-8@5-FU/CUR group exhibited the lowest percentage of COX2-positive cells, representing a prominent reduction compared to the ZIF-8 group (P < 0.0001). Additionally, NOX2 expression was lowest in the ZIF-8@5-FU/CUR group and increased progressively in the ZIF-8@CUR and ZIF-8@5-FU groups. The ZIF-8 group showed the highest proportion of NOX2-positive cells, which was significantly higher compared to that in the ZIF-8@5-FU/CUR group (P < 0.0001) (Figure 5D).Figure 5Immunohistochemical (IHC) analyses of tumor tissues in all four ZIF-8-encapsulated drug formulations. (A) Representative IHC staining images for Ki67, COX2, BAX, and NOX2. (B–E) Percentage of positive cells for (B) Ki67, (C) COX2, (D) NOX2, and (E) BAX, n = 6. Statistical comparisons between two groups were performed using Student’s t-test. ns, not significant; **P < 0.01; ****P < 0.0001.16 micrographs in 4x4 grid, 4 bar graphs showing % of positive cells. Immunohistochemical (IHC) analyses of tumor tissues in all four ZIF-8-encapsulated drug formulations. (A) Representative IHC staining images for Ki67, COX2, BAX, and NOX2. (B–E) Percentage of positive cells for (B) Ki67, (C) COX2, (D) NOX2, and (E) BAX, n = 6. Statistical comparisons between two groups were performed using Student’s t-test. ns, not significant; **P < 0.01; ****P < 0.0001. Unlike the other markers, only minimal brown staining was detected for BAX expression in the ZIF-8 group (Figure 5A). However, BAX-positive cells were elevated in the ZIF-8@CUR and ZIF-8@5-FU groups. BAX expression peaked in the ZIF-8@5-FU/CUR group, reflecting the highest percentage of positively stained cells, a value significantly greater than that of the ZIF-8 group (P < 0.0001) (Figure 5E). Furthermore, no obvious pathological damage was detected in major mouse organs, namely heart, liver, spleen, lungs, or kidneys, across all treatment groups, suggesting favorable in vivo biocompatibility of the ZIF-8-based drug-loaded NPs (Figure 6).Figure 6In vivo safety evaluation of ZIF-8-encapsulated drug-loaded nanoparticles. Hematoxylin and eosin (H&E) staining of major organs.Micrograph grid of stained heart, liver, spleen, lung, kidney tissues; 4 treatments, 200 microm scale bar. In vivo safety evaluation of ZIF-8-encapsulated drug-loaded nanoparticles. Hematoxylin and eosin (H&E) staining of major organs. Discussion This study developed a ZIF-8-based nanoplatform for the co-delivery of 5-FU and CUR to acquire synergistic therapy for HCC. 5-FU was selected because of its ability to block DNA synthesis by inhibiting TS, thereby inducing cell cycle arrest and apoptosis in tumor cells.20,32 CUR was selected due to its anti-inflammatory, antioxidant, and antitumor functions, which facilitate regulation of signaling pathways related to tumor proliferation and apoptosis.23–26 The two drugs offer complementary advantages in exhibiting antitumor activity, providing a strong rationale to construct a responsive nano co-delivery system for synergistic liver cancer therapy. However, the interaction between CUR and 5-FU appears to depend on the combination ratio and tumor cell type, with antagonistic effects observed under certain experimental settings.33,34 These apparently conflicting findings indicate that the antitumor interaction between CUR and 5-FU is context-dependent rather than universally synergistic. Importantly, such variability highlights the need for rational optimization of drug combinations. Our findings provide a promising CUR/5-FU combination strategy. The successful preparation of ZIF-8-based composite nanomaterials was confirmed by field emission scanning electron microscopy (FE-SEM), transmission electron microscopy (TEM) and related characterization techniques. The NPs retained the typical rhombic dodecahedral crystal morphology of ZIF-8, suggesting that drug encapsulation did not disrupt the fundamental structure of the carrier. DLC and EE analyses indicated the feeding ratio of 1:1 (5-FU to CUR) as optimal for a balanced and efficient co-loading of the two drugs. Furthermore, in vitro drug-release experiments confirmed pH-dependent release of both drugs from ZIF-8@5-FU/CUR. Both drugs exhibited substantially lower release at pH 7.4 than under weakly acidic conditions, supporting the pH-responsive release behavior of the nanocarrier. To evaluate the therapeutic efficacy, potential biological basis, and safety of the dual-drug delivery system, both in vitro and in vivo experiments were conducted. In vitro cytotoxicity assay revealed significant concentration-dependent cytotoxicity of ZIF-8@5-FU/CUR against HepG2 cells, with superior efficacy compared with single-drug and blank groups, confirming a strong synergistic effect. In vitro live/dead cell staining further supported these findings, reflecting ~95% cell viability in the blank group, indicative of favorable biocompatibility; the ZIF-8@5-FU/CUR group exhibited only ~10% cell viability. Apoptosis results indicated that the synergistic effect of ZIF-8@5-FU/CUR formulation was primarily mediated by the induction of late apoptosis, reaching as high as 95.3%. Inversely, the late apoptotic rate was considerably lower in the ZIF-8@5-FU (50.0%) and ZIF-8@CUR groups (22.5%). Additionally, hemolysis assays confirmed acceptable hemocompatibility and safe intravenous administration of the combination drugs within the tested concentration range. Within the concentration range of 0–500 μg/mL, the hemolysis rate of ZIF-8@5-FU/CUR was below 3%, well under the 5% hemolysis safety threshold for biomedical materials. In vivo experiments further validated the therapeutic potential of ZIF-8@5-FU/CUR for alleviating tumor consumption. During administration, body weights in the drug-treated groups generally increased, whereas mice in the blank carrier group showed an initial increase followed by a gradual decline, confirming both safety and therapeutic benefits of the drugs. Based on tumor volume and weight measurements, the ZIF-8@5-FU/CUR group achieved significantly greater tumor inhibition relative to single-drug formulations. Histological examination (H&E staining) detected extensive tumor tissue necrosis in the ZIF-8@5-FU/CUR group, compared with only mild and negligible necrosis in single-drug loading and blank groups. These findings highlight the potent tumor-inhibiting effect of the dual-drug co-delivery system. Safety assessment is critical for novel therapeutic systems. H&E staining of major organs revealed no evident histopathological abnormalities in the heart, liver, spleen, lungs, and kidneys across all treatment groups; the tissue morphology was consistent with the normal physiological state. This observation infers that ZIF-8@5-FU/CUR exhibits good in vivo biocompatibility without triggering systemic toxicity. In vitro and in vivo studies focused on evaluating the efficacy, feasibility, and safety of the dual-drug co-delivery system. To further explore the potential biological basis of the synergistic antitumor effect of ZIF-8@5-FU/CUR, the expression levels of Ki67 (cell proliferation-related protein), BAX (pro-apoptosis-related protein), COX2 (pro-inflammatory protein), and NOX2 (oxidative stress-related protein) were analyzed by IHC staining. Minimal expression of Ki67 in the ZIF-8@5-FU/CUR group indicated strong inhibition of tumor cell proliferation. This effect may arise from the complementary actions of the two drugs: 5-FU blocks DNA synthesis and arrests the cell cycle in the S phase, while CUR regulates cyclins and kinases to induce G2/M phase arrest,28 resulting in multi-stage cell cycle blockade. Likewise, maximal BAX protein expression in the ZIF-8@5-FU/CUR group suggests enhanced activation of apoptotic pathways. Mechanistically, 5-FU triggers DNA damage to activate endogenous apoptosis, whereas CUR has been reported to modulate the balance between pro-apoptotic and anti-apoptotic proteins, including upregulation of BAX and downregulation of Bcl-2.35 Previous studies of CUR combined with 5-FU have further demonstrated enhanced Bax expression, reduced Bcl-2 expression, and increased activation of downstream apoptotic proteins, supporting the involvement of the Bcl-2/BAX-caspase axis in the enhanced apoptotic response.36–38 Consistent with these findings, the highest BAX expression and strongest apoptotic response were observed in the ZIF-8@5-FU/CUR group, suggesting the possible presence of Bcl-2/BAX-caspase axis which may contribute to the enhanced antitumor activity of the combination. Regarding TME, inflammation and oxidative stress are two main risk factors modulating tumor growth and invasion. The lowest expression of COX2 and NOX2 in the ZIF-8@5-FU/CUR group suggests attenuation of inflammation- and oxidative-stress-associated responses following combination treatment. Notably, a previous study specifically investigating the combination of CUR and 5-FU in HCC reported enhanced antitumor activity accompanied by suppression of NF‑κB and COX-2 expression.33 These findings provide a potential mechanistic link between the two agents and are consistent with the reduced COX2 expression observed in our combination group. Other upstream pathways may also contribute to the enhanced response to the combination. A previous study in HepG2 cells reported that hydrazinocurcumin, a curcumin analogue, combined with 5-FU promoted apoptosis through upregulation of PTEN and suppression of PI3K/AKT signaling.39 Although hydrazinocurcumin is not identical to native CUR, these findings suggest that PTEN/PI3K/AKT signaling may represent a potential regulatory axis underlying the enhanced apoptotic response to CUR and 5-FU. Although this study successfully constructed a pH-responsive drug co-delivery system of ZIF-8@5-FU/CUR and confirmed its in vitro and in vivo synergistic anti-liver cancer effects, there are still some limitations. First, the exploration of the molecular mechanism of the synergy between 5-FU and CUR in this study is still relatively superficial. In this study, protein expression analysis was limited to markers associated with proliferation, apoptosis, inflammation, oxidative stress, and the specific molecular mechanisms of the two drugs in regulating drug metabolism and signal pathway crosstalk were not explored in depth. Follow-up studies need to further explore the complete molecular mechanism of synergistic anti-tumor effects by combining targeted detection of upstream functional proteins with transcriptomic high-throughput profiling. Second, although the present in vivo experiment falls within the scope of a preclinical antitumor efficacy study,40 the lack of overall survival assessment limits the clinical relevance of the present findings. Future studies with a dedicated survival cohort are warranted to determine whether ZIF-8@5-FU/CUR can prolong survival. Conclusion In this study, a ZIF-8-based nanoscale dual-delivery system co-encapsulating 5-FU and CUR was successfully fabricated. The system demonstrated enhanced antitumor efficacy against HCC, which was associated with inhibition of tumor-cell proliferation, promotion of apoptosis, and attenuation of inflammation- and oxidative-stress-associated responses, as reflected by altered Ki67, BAX, COX2, and NOX2 expression. Based on these findings and previous mechanistic studies, the enhanced activity of 5-FU and CUR may involve complementary regulation of survival, inflammatory, and apoptotic signaling, including potential involvement of the NF-κB/COX-2, Bcl-2/BAX-associated pathways and the PTEN/PI3K/AKT pathway. Nevertheless, these upstream signaling pathways were not directly validated in the present study, and further pathway-specific studies are required to establish their precise contributions to the synergistic antitumor effect. The ZIF-8 nanocarrier enabled co-delivery and synchronized drug release of the two therapeutic agents, contributing to enhanced antitumor activity with favorable biocompatibility. This study provides a promising approach for HCC treatment and highlights the potential of MOF-based nanocarriers in precision nanomedicine. Further optimization of targeting strategies and mechanistic exploration may facilitate the clinical translation of this nanoplatform in HCC treatment.